Primers on Pathogens: Ebola Virus: Origin, Structure, Transmission, Prevention, and Surrogate Testing

Ebola disease is a rare but severe viral illness that can cause major public health emergencies when outbreaks are not detected and controlled early. It is associated with high fatality rates, healthcare-worker risk, strict infection prevention requirements, and the need for rapid laboratory confirmation, isolation, contact tracing, safe patient care, and environmental control.

Recent outbreaks have again highlighted the importance of Ebola preparedness. In May 2026, the World Health Organization (WHO) was alerted to a high-mortality outbreak of unknown illness in Ituri Province, Democratic Republic of the Congo (DRC), including deaths among healthcare workers. Laboratory testing later confirmed Bundibugyo virus disease, a form of Ebola disease caused by Bundibugyo virus. WHO determined that the outbreak in DRC and Uganda constituted a Public Health Emergency of International Concern on 17 May 2026. [4,5]

As of 2 June 2026, Reuters reported that WHO had identified 321 confirmed cases and 116 suspected cases in DRC, with 48 deaths and six recoveries. Uganda’s Ministry of Health reported 15 confirmed cases, one death, two discharges, and 12 people still in care. These numbers are time-sensitive and may change as surveillance and laboratory confirmation continue. [6,7]

Although Ebola does not usually spread through casual contact, it remains a high-consequence pathogen because transmission can occur through direct contact with blood, body fluids, contaminated materials, unsafe burial practices, and healthcare exposure when infection prevention measures are not strictly followed. [1,2]

Origin and History

Ebola disease was first recognized in 1976 during two near-simultaneous outbreaks: one in Nzara, in what is now South Sudan, and another in Yambuku, in what is now the Democratic Republic of the Congo. The name “Ebola” comes from the Ebola River near the Yambuku outbreak region. [1]

The natural reservoir has not been confirmed with complete certainty, but fruit bats are considered the most likely natural hosts. Human spillover may occur through contact with infected wildlife, including bats, non-human primates, forest antelope, porcupines, or animals found sick or dead in affected regions. Once introduced into people, Ebola can spread through direct contact with infectious body fluids or contaminated materials. [1,4]

Since 1976, Ebola outbreaks have occurred intermittently, mainly in Central and West Africa. The 2014–2016 West Africa outbreak was the largest Ebola outbreak recorded and demonstrated how quickly transmission can expand when early detection, laboratory confirmation, isolation, contact tracing, community engagement, and healthcare infection control are delayed.

Virus Structure and Types

Ebola viruses belong to the family Filoviridae and the genus Orthoebolavirus. Filoviruses are known for their filamentous, thread-like appearance under electron microscopy. Ebola viruses are enveloped viruses with a non-segmented, negative-sense, single-stranded RNA genome. They are not DNA viruses, and they are not non-enveloped viruses. [1–3]

Several orthoebolaviruses have been identified. Four are known to cause illness in people. [1,2]

This distinction is important because vaccines and therapeutics are not equally available for all Ebola-related viruses. WHO notes that approved vaccines and treatments are available for Ebola virus disease caused by Ebola virus, but not for other Ebola diseases such as Sudan virus disease or Bundibugyo virus disease. [1]

Transmission

People with Ebola disease are generally considered infectious after symptoms begin. The incubation period is usually 2 to 21 days. Early symptoms can include fever, fatigue, muscle pain, headache, and sore throat, followed by vomiting, diarrhea, rash, impaired liver and kidney function, and sometimes bleeding. Because early symptoms can resemble many other febrile illnesses, laboratory confirmation is essential. [1,2]

Transmission can occur through direct contact with:

• Blood or body fluids from a person who is sick with or has died from Ebola disease
• Vomit, feces, urine, saliva, sweat, breast milk, semen, amniotic fluid, or vaginal fluid
• Contaminated needles, syringes, bedding, clothing, medical equipment, or surfaces
• Bodies of deceased infected individuals during unsafe funeral or burial practices
• Infected wildlife or raw meat from infected animals in endemic regions [1,2]

Recent Outbreak Risk and International Spread

The 2026 Bundibugyo virus disease outbreak in DRC and Uganda shows how Ebola can become a regional concern when detection is delayed and population movement is high. WHO reported that the event likely originated in Mongbwalu Health Zone, a high-traffic mining area in Ituri Province, DRC. The first currently known suspected case was a healthcare worker who developed symptoms in April 2026 and later died. Cases were later identified in other areas as people sought medical care. [4]

WHO assessed the risk as very high for DRC, high for Uganda, high for countries sharing land borders with affected countries, and low for all other countries. WHO did not recommend suspension of flights or denial of entry for travellers from affected countries. Instead, WHO emphasized targeted surveillance, exit screening where appropriate, contact monitoring, isolation and referral pathways, laboratory readiness, community engagement, safe burial practices, and strong healthcare infection prevention and control. [5]

For countries outside the affected region, the main priorities are preparedness and early recognition: informing healthcare providers and travellers, asking about recent travel in patients with compatible symptoms, isolating suspected cases quickly, arranging safe testing and referral, and protecting healthcare workers through appropriate PPE and procedures. [5]

Prevention and Control

Ebola prevention requires layered controls. No single measure is enough.

In community and outbreak settings, best practice includes rapid identification and isolation of suspected cases, laboratory confirmation, contact tracing and 21-day monitoring, safe and dignified burial practices, community engagement, avoidance of contact with sick or dead wildlife, and accurate risk communication that does not stigmatize affected communities. [1,5]

In healthcare settings, prevention requires early screening and triage, immediate isolation of suspected or confirmed cases, appropriate PPE, hand hygiene, safe injection practices, safe handling of contaminated linens and waste, environmental cleaning and disinfection, and staff training for donning and doffing PPE. [1,5]

For environmental disinfection, Ebola’s lipid envelope makes it susceptible to appropriately selected disinfectants. However, effectiveness depends on product selection, concentration, contact time, surface type, soil load, and correct application. EPA maintains List L for disinfectants with Ebola virus claims and List Q for disinfectants with emerging viral pathogen claims. EPA classifies viruses causing Ebola disease as Tier 1 enveloped viruses, which are generally the easiest category of viruses to inactivate when the disinfectant damages the lipid envelope. [8,9]

Surrogate Testing: Why CREM Co Labs Uses MVA

Direct efficacy testing with live Ebola virus requires maximum-containment facilities and is not practical for routine product development, antimicrobial surface evaluation, disinfectant screening, or technology comparison. Therefore, safer surrogate viruses are commonly used to generate practical and scientifically defensible efficacy data.

For CREM Co Labs’ efficacy testing programs, Modified vaccinia virus Ankara (MVA) is a strong and practical surrogate for Ebola-related enveloped-virus efficacy testing.

MVA is not Ebola virus. It is an attenuated, enveloped vaccinia virus and has a DNA genome, whereas Ebola is an enveloped RNA virus. However, for disinfectant and environmental efficacy testing, the most important shared feature is the presence of a lipid envelope. Disinfectants that effectively damage or disrupt the viral envelope can prevent enveloped viruses from remaining infectious. [8,9]

MVA is recommended because it is:

• Enveloped, matching the key structural vulnerability of Ebola viruses
• Safer and more practical to handle than live Ebola virus
• Well characterized
• Suitable for controlled laboratory efficacy studies
• More practical for routine testing than maximum-containment Ebola work
• Useful as a conservative enveloped-virus challenge for product development and comparative testing

CREM Co Labs has the capability to perform efficacy testing using Modified vaccinia virus Ankara (MVA). This supports product development and validation work for disinfectants, antimicrobial surfaces, textiles, devices, environmental technologies, and comparative infection prevention research where an enveloped-virus surrogate is appropriate.

It is important to state this accurately: MVA testing should be described as surrogate efficacy testing, not direct Ebola virus testing. Publicly available head-to-head publications comparing MVA-based disinfectant efficacy directly with live Ebola virus efficacy are limited. The scientific rationale is based on envelope biology, established virucidal testing principles, the hierarchy of viral resistance used in regulatory frameworks, and the impracticality of routine live Ebola testing outside specialized containment laboratories. [8,9]

Conclusion

Ebola viruses are enveloped, filamentous, negative-sense RNA viruses capable of causing severe and often fatal disease. Since their discovery in 1976, Ebola-related viruses have caused repeated outbreaks, mainly in Central and West Africa. Transmission occurs mainly through direct contact with infected blood, body fluids, contaminated materials, unsafe burial practices, or infected animals.

The 2026 Bundibugyo virus disease outbreak in DRC and Uganda reinforces the importance of preparedness, surveillance, infection prevention, safe healthcare practices, environmental disinfection, and community engagement. While WHO currently assesses the risk to countries outside the affected and neighbouring regions as low, rapid recognition and safe response remain essential.

For efficacy testing, MVA is a practical and scientifically defensible Ebola surrogate because it is enveloped, safer to handle, well characterized, and suitable for controlled laboratory studies. CREM Co Labs’ MVA testing capability provides clients with a valuable pathway to evaluate products and technologies intended to support infection prevention against high-consequence enveloped viruses.

References

1. World Health Organization. Ebola disease. Fact sheet. Geneva: WHO; 2025 Apr 24.
2. Centers for Disease Control and Prevention. Ebola Disease Basics. Atlanta: CDC; 2026 Jun 2.
3. International Committee on Taxonomy of Viruses. Filoviridae. ICTV Report. London: ICTV; 2026.
4. World Health Organization. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda. Disease Outbreak News. Geneva: WHO; 2026 May 16.
5. World Health Organization. First meeting of the IHR Emergency Committee regarding the epidemic of Ebola Bundibugyo virus disease in the Democratic Republic of the Congo and Uganda 2026: temporary recommendations. Geneva: WHO; 2026 May 22.
6. Le Poidevin O, Rigby J. WHO says suspected Ebola cases drop to 116 after hundreds ruled out. Reuters. 2026 Jun 2.
7. Biryabarema E, Le Poidevin O. Uganda health ministry confirms six new cases of Ebola. Reuters. 2026 Jun 2.
8. United States Environmental Protection Agency. EPA’s registered antimicrobial products effective against Ebola virus: List L. Washington, DC: EPA; 2026.
9. United States Environmental Protection Agency. Disinfectants for Emerging Viral Pathogens: List Q. Washington, DC: EPA; 2026.
10. United States Food and Drug Administration. JYNNEOS: smallpox and mpox vaccine, live, non-replicating. Silver Spring, MD: FDA; 2025 May 14.